Ay Cihan, Ünal Umut Kaan
aDepartment of Medicine I, Clinical Division of Haematology and Haemostaseology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria bIstanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey.
Curr Opin Oncol. 2016 Mar;28(2):145-9. doi: 10.1097/CCO.0000000000000262.
Cancer is a strong risk factor for venous thromboembolism (VTE). In patients with lung cancer VTE is a significant cause for morbidity and mortality. The purpose of the review is to summarize the epidemiology of thrombotic events, risk factors for VTE and the clinical impact of VTE in patients with lung cancer.
The rates of VTE in lung cancer patients vary according to different types of investigations, and reach 7 to 13%, including a significant number of unsuspected pulmonary emboli. Risk factors for VTE in patients with lung cancer can be basically divided into three categories: patient, tumor, and treatment related. In addition, a number of biomarkers have been described to be associated with VTE risk (e.g., D-dimer).
Knowledge about the epidemiology, risk factors, and prognostic value of VTE in lung cancer could help to prevent thrombotic complications and improve management of patients with lung cancer.
癌症是静脉血栓栓塞症（VTE）的一个重要危险因素。在肺癌患者中，VTE是发病和死亡的一个重要原因。本综述的目的是总结肺癌患者血栓形成事件的流行病学、VTE的危险因素以及VTE对肺癌患者的临床影响。
肺癌患者中VTE的发生率因调查类型不同而有所差异，可达7%至13%，其中包括大量未被怀疑的肺栓塞。肺癌患者发生VTE的危险因素基本可分为三类：患者因素、肿瘤因素和治疗相关因素。此外，一些生物标志物已被描述与VTE风险相关（如D-二聚体）。
了解肺癌中VTE的流行病学、危险因素和预后价值有助于预防血栓形成并发症并改善肺癌患者的管理。
